 |
|
 |
 |

Home > Company Index > Drugs > Drug Manufacturers - Other > Hemispherx Biopharma, Inc.
 |
Hemispherx Biopharma, Inc. |
 |
 |
 |
PROFILE |
 |
Hemispherx Biopharma is doing a world of good with its RNA drugs. The development-stage company is working with Bioclones Proprietary to develop Ampligen, an intravenously administered RNA drug, to treat hepatitis B and C, HIV, chronic fatigue syndrome, and certain cancers. Hemispherx, together with Temple University scientists, is also working on Oragen, a broad spectrum antiviral. In addition to its RNA drugs, the company is developing laboratory tests using RNA to detect viral infections. Hemispherx has other collaborative agreements with Biovail and Gentiva Health Services.
COMPETITION |
 |
Genentech, Inc. (DNA)
Gilead Sciences, Inc. (GILD)
Isis Pharmaceuticals, Inc. (ISIP)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.80
1-Yr. Sales Growth: 14.3%
Employees: 48
Revenue per employee: $16,666.67
KEY PEOPLE |
 |
William A. Carter
CEO
Robert E. Peterson
CFO
CONTACT INFO |
 |
1 Penn Center
Philadelphia, PA 19103
US
Phone: 215-988-0080
Fax: 215-988-1739
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |